Form 4: Esperion Therapeutics CFO Benjamin Halladay Reports Stock and Option Awards

Esperion Therapeutics' CFO, Benjamin Halladay, reports the acquisition of stock and option awards, along with shares acquired through the Employee Stock Purchase Plan.

Summary

• Benjamin Halladay, CFO of Esperion Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On March 14, 2025, Halladay acquired 238,000 shares of common stock and options to purchase 213,000 shares at an exercise price of $1.50.
• The stock award vests over four years in equal quarterly installments, starting June 15, 2025.
• Halladay also reported owning 485,245 shares of common stock, including 6,574 shares acquired through the Employee Stock Purchase Plan.
• The filing was signed on Halladay's behalf by Sheldon L. Koenig, under a power of attorney dated November 16, 2022.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports routine transactions. The acquisition of shares and options by the CFO could be interpreted as a mildly positive signal.

Positives

• The acquisition of stock and options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
• Participation in the Employee Stock Purchase Plan demonstrates a commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Stakeholder Impact

• The reported transactions may have a minor positive impact on shareholder sentiment.

Key Dates